MAPT and glioblastoma: Given the interactions demonstrated by flavonoids with the Tau protein, we have opted for thiazoloflavonoid hybrid derivatives, some molecules in which a thiazole group is integrated into the flavonoid heterocycle, as our initial candidates, and we have demonstrated their therapeutic potential in a cancer model overexpressing Tau protein, such as GBM [26,27,28].